301 related articles for article (PubMed ID: 21420318)
1. Five-year outcomes with alemtuzumab induction after lung transplantation.
Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
[TBL] [Abstract][Full Text] [Related]
3. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
4. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.
McCurry KR; Iacono A; Zeevi A; Yousem S; Girnita A; Husain S; Zaldonis D; Johnson B; Hattler BG; Starzl TE
J Thorac Cardiovasc Surg; 2005 Aug; 130(2):528-37. PubMed ID: 16077423
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study.
Jaksch P; Ankersmit J; Scheed A; Kocher A; Muraközy G; Klepetko W; Lang G
Am J Transplant; 2014 Aug; 14(8):1839-45. PubMed ID: 25039364
[TBL] [Abstract][Full Text] [Related]
6. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
9. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
12. Early outcomes using alemtuzumab induction in lung transplantation.
van Loenhout KC; Groves SC; Galazka M; Sherman B; Britt E; Garcia J; Griffith B; Iacono A
Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):190-4. PubMed ID: 19939852
[TBL] [Abstract][Full Text] [Related]
13. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
14. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.
Chan K; Taube D; Roufosse C; Cook T; Brookes P; Goodall D; Galliford J; Cairns T; Dorling A; Duncan N; Hakim N; Palmer A; Papalois V; Warrens AN; Willicombe M; McLean AG
Transplantation; 2011 Oct; 92(7):774-80. PubMed ID: 21836540
[TBL] [Abstract][Full Text] [Related]
15. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
Sampaio MS; Chopra B; Sureshkumar KK
Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab.
Brock MV; Borja MC; Ferber L; Orens JB; Anzcek RA; Krishnan J; Yang SC; Conte JV
J Heart Lung Transplant; 2001 Dec; 20(12):1282-90. PubMed ID: 11744411
[TBL] [Abstract][Full Text] [Related]
17. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
[TBL] [Abstract][Full Text] [Related]
18. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
Noël C; Abramowicz D; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Hazzan M
J Am Soc Nephrol; 2009 Jun; 20(6):1385-92. PubMed ID: 19470677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]